mounjaro glp 1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 is mounjaro glp 1 drug
Description
Fatigue is another commonly reported experience, particularly during the first weeks of treatment or after dose increases
Several pharmaceutical companies had GLP-1 programs, but Novo Nordisks liraglutide became the next major product to reach the market
For patients, the implications are far-reaching
Graefes Arch Clin Exp Ophthalmol
